Prescription medication · Anti-IL-23 Monoclonal Antibody
risankizumab
Also sold as Skyrizi. Skyrizi is used to treat moderate to severe plaque psoriasis in adults.
Data updated 2026-05-15
- $20211.78
- Brand price (NADAC)
risankizumab (Skyrizi) is a prescription Anti-IL-23 Monoclonal Antibody. Skyrizi is used to treat moderate to severe plaque psoriasis in adults.
Skyrizi is a medicine that can help reduce inflammation in your body. It is used to treat conditions like psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.
Verify with FDA → · CMS NADAC pricing →
Drug Pricing (NADAC)
Brand Price
$20211.78/unit
Generic Available
No
Pricing data from NADAC (CMS), effective December 18, 2024. Compare all drug costs →
What it does
Skyrizi is used to treat moderate to severe plaque psoriasis in adults.
Common side effects
Upper respiratory infections (like a cold), Headache, Fatigue
Key warnings
Serious allergic reactions, including anaphylaxis, can happen.
The sections below are summarized in plain English from risankizumab's FDA-approved prescribing information. They describe what the official label says, and are not personal medical advice.
How It Works
Skyrizi is a type of antibody that blocks a protein called interleukin-23 (IL-23). IL-23 causes inflammation in the body. By blocking IL-23, Skyrizi helps to reduce inflammation and the symptoms of certain diseases.
How to Take It
For psoriasis and psoriatic arthritis, you will get a 150 mg injection under your skin. You'll get it at Week 0, Week 4, and then every 12 weeks. For Crohn's disease and ulcerative colitis, you will first get infusions into your vein. After that, you will get injections under your skin every 8 weeks.
This is a plain-language summary of risankizumab's FDA labeling, not individualized dosing advice. Ask a pharmacist or prescriber before changing how you take this medication.
Pregnancy & Breastfeeding
Tell your doctor if you are pregnant or plan to become pregnant. It is not known if Skyrizi will harm your unborn baby. There is a pregnancy registry to track outcomes in women who use Skyrizi during pregnancy. Call 1-877-302-2161 to enroll.
This is a plain-language summary of risankizumab's FDA labeling, not individualized advice. Ask a pharmacist or prescriber about pregnancy or breastfeeding on this medication.
Missed Dose
If you miss a dose of Skyrizi, talk to your doctor right away. They will tell you when to take your next dose.
This is a plain-language summary of risankizumab's FDA labeling, not individualized advice. Ask a pharmacist or prescriber what to do about your specific missed dose.
Storage
Store Skyrizi in the refrigerator between 36°F and 46°F (2°C and 8°C). Do not freeze or shake it. Keep it in its original carton to protect it from light.
Serious Warnings
Serious allergic reactions, including anaphylaxis, can happen. If you have an infection, tell your doctor. Skyrizi may increase your risk of getting an infection or make an existing infection worse. Your doctor will check you for tuberculosis (TB) before you start Skyrizi. For inflammatory bowel disease, Skyrizi can cause liver problems. Your doctor will check your liver before and during treatment.
Common Questions
What should I tell my doctor before taking Skyrizi?
Can I get vaccines while taking Skyrizi?
What are the symptoms of an allergic reaction?
How often will I need to get injections?
Will Skyrizi cure my condition?
Can I take Skyrizi with other medications?
What if I have side effects?
How long does Skyrizi stay in my system?
Can Skyrizi affect my immune system?
What tests will I need before starting Skyrizi?
What are the common side effects of risankizumab?
What drug class is risankizumab?
Is risankizumab safe during pregnancy?
Related Medications in Anti-IL-23 Monoclonal Antibody
Other drugs grouped near risankizumab - same-class peers and common alternatives.
adapalene
Differin
Compare with risankizumab →
apremilast
Otezla
Apremilast (Otezla/Otezla XR) is a medicine that can help adults and children manage psoriatic arthritis and psoriasis.
Compare with risankizumab →
azelaic acid
Finacea, Azelex
Azelaic acid gel is a topical medicine that helps treat rosacea.
Compare with risankizumab →
benzoyl peroxide
Benzac, PanOxyl
Benzoyl peroxide is a topical medicine that fights germs on your skin.
Compare with risankizumab →
betamethasone
Diprosone, Luxiq
Betamethasone dipropionate cream is a strong steroid medicine used on the skin.
Compare with risankizumab →
Medication Guides
Understanding Drug Interactions
How CYP450 enzymes, inhibitors, and inducers affect your medications
Generic vs Brand Name Drugs
FDA requirements, cost savings, and when the difference matters
Narrow Therapeutic Index Drugs
Why some drugs demand precise dosing and monitoring
Common Drug Interactions
Dangerous medication combinations and how to protect yourself
Save on risankizumab
Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.
Disclosure: This link may earn us a commission at no extra cost to you. See our terms.
What the FDA Data Shows for risankizumab
The FDA label for risankizumab (sold under brand names such as Skyrizi) classifies it as a prescription-only medication in the Anti-IL-23 Monoclonal Antibody class. Skyrizi is used to treat moderate to severe plaque psoriasis in adults. Official labeling lists 5 commonly reported side effects, including Upper respiratory infections (like a cold), Headache, Fatigue.
Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. Voluntary reports accumulate over the lifetime of a drug and reflect wide-ranging clinical use. Interaction data is drawn directly from FDA-approved prescribing information. NADAC pricing from CMS.
Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information further shape supply and switching decisions. This page summarizes public FDA data for educational purposes only and is not a substitute for professional medical advice, always consult a licensed healthcare provider before starting, stopping, or changing any medication.
Data Sources
Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS). Pricing: CMS National Average Drug Acquisition Cost (NADAC).
FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. Always consult a healthcare professional before making medication decisions.
Last updated: September 3, 2025
Read our methodology - how this data is sourced, computed, and verified.
Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled and last refreshed May 2026. See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
All federal data sources used on this page
- FDA Orange Book - approved drug products with therapeutic equivalence. accessdata.fda.gov/cder/ob
- FDA DailyMed - NIH-hosted drug labeling for FDA-approved meds. dailymed.nlm.nih.gov
- FDA Adverse Event Reporting System (FAERS) - post-marketing safety surveillance. fda.gov/drugs/faers
- NLM RxNorm - standardized clinical drug nomenclature. nlm.nih.gov/research/umls/rxnorm
- CMS Medicare Part B Drug Average Sales Price Files - federal drug pricing data. cms.gov/medicare/part-b-drugs/asp
- FDA Drug Shortages Database - current and resolved drug shortage tracking. accessdata.fda.gov/drugshortages